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Aluminum removal by peritoneal dialysis: Intravenous vs. intraperi-
toneal deferoxamine. Aluminum removal via pentoneal dialysis was
evaluated after the administration of deferoxarninc in patients treated
with CAPD and CCPD. The intravenous administration of
deferoxamine, 40 mg/kg, led to a 730 139% increase in aluminum
removal, compared to an increase of 641 178% after the drug was
administered intraperitoneally. The mean dialysate:plasma concentra-
tion ratio for aluminum rose from 0.17 0.03 to 0.32 0.03 with
intravenous deferoxamine administration, and from 0.19 0.05 to 0.38
0.07 with the intraperitoneal instillation of deferoxamine. In the
seven patients with paired studies using both modalities of administra-
tion, there were no significant differences in the increments in plasma
aluminum or in aluminum removal over a 24-hour period. In patients
from whom effluent dialysate was collected for several days after the
administration of deferoxamine, daily aluminum losses increased from
218 76 g/24 hours before the administration of desferrioxamine to
1521 339, 1120 232, and 948 328 .tg/24 hours over three
successive days after deferoxamine. These data indicate that aluminum
is effectively removed after the administration of either intravenous or
intraperitoneal deferoxamine. The enhanced rate of removal of alumi-
num by peritoneal dialysis persists for several days after a single dose
of deferoxamine. The efficacy and safety of long—term treatment with
intraperitoneal deferoxamine requires further study.
Aluminum—related bone disease has been noted mainly in
patients on maintenance hemodialysis, although it has been
described in patients treated with continuous ambulatory pen-
toneal dialysis [1—3]. The removal of aluminum after the admin-
istration of defcroxamine by either hemodialysis or peritoneal
dialysis treatment results in improvement of aluminum—related
bone disease and encephalopathy [2—5].
The rates of aluminum removal after the intravenous admin-
istration of deferoxamine have not been well characterized in
patients undergoing peritoneal dialysis; moreover, no data are
available on the relative effectiveness of the intraperitoneal
compared to the intravenous route of administration of desfer-
rioxamine in the removal of aluminum.
Since deferoxamine has been administered by different
routes, that is, intravenous, intraperitoneal, oral, rectal, and
subcutaneous for the treatment of patients with evidence of iron
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overload [6.-ill it seems reasonable to postulate that the
intraperitoneal administration of deferoxamine would also be
effective in enhancing the removal of aluminum. Therefore, we
examined the use of deferoxamine in augmenting the removal of
aluminum by peritoneal dialysis and compared the intravenous
and intraperitoneal routes of administration.
Methods
A total of 19 patients, 10 males and nine females, ranging in
age from 12 to 66 years (mean SEM, 40.1 4.5 years),
participated in the study. Fifteen patients were undergoing
treatment with CAPD, performed according to the technique
described by Oreopoulos et al [121. Briefly, each patient re-
ceived four or five exchanges of 2 liters each on a daily basis.
The other four patients were treated with continuous cycling
peritoneal dialysis (CCPD). This dialysis regimen, described in
detail elsewhere [13], involved five two—hour nocturnal cycles
(AMP 80/2; American Medical Products, Freehold, New Jer-
sey, USA) and a single daytime dwell with the same dialysate as
used for CAPD (Dianeal; Travenol Laboratories, Deerfield,
Illinois, USA) and a volume half that given during nocturnal
cycles, The patients had been treated with peritoneal dialysis
for 12 to 60 months (mean, 36.4 3.0 months), with a duration
of total dialysis treatment (peritoneal dialysis plus hemodial-
ysis) of 12 to 192 months (mean, 69.2 11.6 months).
Thirteen patients had biopsy proven aluminum—related bone
disease and received the deferoxamine prior to initiation of
long—term chelation therapy. Six patients were given the med-
ication as part of a deferoxamine infusion test to evaluate for
the presence of aluminum overload [14]. Fifteen of the 19
patients received deferoxamine intravenously and 11 received it
by the intraperitoneal route; seven patients received the medi-
cation by both routes of administration. Among this latter group
of seven patients, four received deferoxamine intraperitoneally
first, the other three by the intravenous route initially. The two
methods of administration were evaluated four to eight weeks
apart, with no deferoxamine given during the intervening pe-
riod.
The patients were admitted for study to the Special Diagnos-
tic and Treatment Unit of the West Los Angeles VA Medical
Center or to the Clinical Research Center of the UCLA Center
for the Health Sciences. Aluminum—containing phosphate—
binding agents were discontinued during this time. Informed
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consent was obtained from all patients and in the case of
minors, from their parents. These studies were approved by the
UCLA Human Subject Protection Committee and the VA
Wadsworth Human Use Committee.
Fifteen patients were administered an intravenous infusion of
deferoxamine, 40 mg/kg body wt diluted in 100 ml of 5%
dextrose in water, over two hours. Vital signs were monitored
every 15 minutes during the first hour and every 30 minutes
over the second hour. Mter the start of the infusion, the
peritoneal cavity was emptied for six and 10 hours in patients
treated with CAPD and CCPD respectively; thereafter, the
regular exchanges were resumed. Plasma aluminum levels were
obtained both before and 24 hours after the start of the infusion.
The effluent dialysate was collected for the 24 hours preceding
the infusion of deferoxamine and for the 24 hours after the
exchanges were resumed.
Deferoxamine, 40 mg/kg body wt, was added to the regular
dialysate solution, and following intraperitoneal instillation was
allowed to dwell eight to 10 hours overnight in the patients
treated with CAPD and for 10 hours during the day in patients
receiving CCPD therapy. Vital signs were obtained hourly for
six hours after the instillation of deferoxamine. Plasma was
obtained for aluminum measurement before the deferoxamine
was given and 24 hours after its instillation. Effluent dialysate
was collected for the 24 hours prior to the instillation of
deferoxamine and for the 24 hours after regular exchanges were
resumed.
In the patients treated with CAPD, each bag of effluent
dialysate was individually weighed, as a measure of volume
[15], and a sample obtained for aluminum determination. The
CCPD drainage volume was determined volumetrically and a
sample from the complete 24-hour exchange volume was ob-
tained for aluminum measurement.
In 11 patients, the collections were carried out for longer than
24 hours after the administration of deferoxamine. In five of the
11 patients the deferoxamine was administered intravenously,
while six received it intraperitoneally. In all 11, the collections
were obtained 24 to 48 hours after the infusion of deferoxamine;
in six, dialysate was collected from 48 to 72 hours, and the
collection was continued from 72 to 96 hours in one.
Aluminum concentrations were measured, as previously re-
ported [161, using flameless atomic absorption spectroscopy.
The plasma aluminum concentration in normal volunteers is
less than 8 g/liter in our laboratory [14]. Aluminum levels in
nine lots of unused dialysate solution of varying dextrose
concentrations, either DianealR (Travenol Laboratories, Deer-
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Fig. 1. The concentrations of plasma aluminum before and 24 hours
after either the intravenous (i.v.) route (0) or the intraperitoneal (i.p.)
route (I)ofadministration of deferoxamine (DFO). Values are mean
SEM, and there were 15 studies with i.v. and 11 studies with i.p.
deferoxamine.
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Fig. 2. The rates of removal of aluminum during peritoneal dialysis(PD) both before and after either the intravenous (i.v.) route (0) or
intraperitoneal (i.p.) route (I) of administration of deferoxamine(DFO). Number of studies are as in Figure 1.
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Fig. 3. The dialvsate:plasma concentration ratios for aluminum before
and after either the intravenous (0) or the inrraperitoneal (•) admin-
istration of deferoxamine (DFO). Symbols and the number of studies
are the same as in Figure 1.
field, Illinois, USA) or ImpersoiR (Abbott Laboratories, North
Chicago, Illinois, USA) were less than 6 pg/liter.
There were no statistically significant differences between the
results of studies undertaken during CAPD or CCPD therapy;
therefore, the data were pooled for analysis. Similarly, in the
patients receiving deferoxamine by both routes of administra-
tion, there was no statistical difference in the results obtained
no matter which route was used first. In the patients in whom
effluent dialysate was collected over several days following a
single dose of deferoxamine, there was no significant difference
in the aluminum removal rates with the two modes of adminis-
tration; therefore, these results were also pooled for analysis.
Statistical analyses were carried out using paired or unpaired
Student t-tests where appropriate. Data are reported as mean
SEM.
Results
The changes in mean plasma aluminum concentration, the
increments in total aluminum removal by effluent dialysate, and
the dialysate:plasma concentration ratios for aluminum before
and after the intraperitoneal or intravenous administration of
deferoxamine are shown in Figures 1, 2, and 3, respectively.
Following the intravenous administration of deferoxamine,
the mean plasma aluminum concentration increased by 273
44%, from the pre-infusion level of 240.8 110.1 to 640.1
179.2 LgIliter (P <0.001). Total aluminum removal in effluent
dialysate increased by 730 139% from 407.3 230,0 sg/24
hours before the intravenous administration of deferoxamine to
1723.2 471.9 g/24 hours afterwards (P < 0.001). The mean
dialysate:plasma concentration ratio for aluminum rose from
0.17 0.03 before the deferoxaminc infusion to 0.32 0.03
afterwards (P < 0.001).
After the intraperitoneal administration of deferoxamine,
plasma aluminum increased by 346 78% from a baseline
concentration of 156.1 49.6 to 637.9 140.9 jrg/liter (P <
0.001). Total aluminum removal in the dialysate increased by
641 178% from the pretreatment rate of 262.1 72.5 to 1379.0
333.7 jg/24 hours (P < 0.005). After the administration of
deferoxamine, the mean dialysate:plasma concentration ratio of
aluminum increased from 0.19 0.05 to 0.38 0.07 (P < 0.05).
There were no significant differences between any of these
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Fig. 4. The rates of removal of aluminum during peritoneal dialysis
before (PRE DFO) and several days after the administration of
deferoxamine (DFO). The number of patients (]Vi studied is shown
along the abscissa; six patients received deferoxamine intravenously
and five patients received it by the intraperitoneal route, and the data
are combined.
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three parameters, comparing the changes after intraperitoneal
versus intravenous routes of administering deferoxamine.
The changes in plasma aluminum concentration and the
increments in aluminum removal were very similar after the
intravenous compared to the intraperitoneal route of adminis-
tration in the seven patients who received deferoxamine by
both routes. Thus, the administration of deferoxamine intrave-
nously and intraperitoneally resulted in an increase in plasma
aluminum of 361 77% and 333 77%, respectively. Alumi-
num removal increased by 895 256% after intravenous
deferoxamine and by 827 273% after its intraperitoneal
instillation.
Aluminum removal over several days after one dose of
deferoxamine are shown in Figure 4. The rate of aluminum
removal was 218 76 /.g/24 hours before deferoxamine; after
its infusion, aluminum removal increased to 1521 339 gI24
hours during the first day, 1120 232 g/24 hours during the
second day, 948 328 p.g124 hours during the third. The
aluminum removal rate was 850 gI24 hours on the fourth day
in one patient.
There was no change in vital signs noted during both the
intravenous and intraperitoneal administration of deferox-
amine. The patients tolerated the procedures well, and no
adverse effects were noted.
Discussion
Aluminum—related bone disease is not an uncommon compli-
cation in patients receiving maintenance hemodialysis treat-
ment [171. Initially, most cases were reported in patients treated
with hemodialysis, but more recently patients undergoing treat-
ment with peritoneal dialysis have been identified as having a
similar syndrome. Previous studies have shown that intrave-
nous deferoxamine enhances aluminum removal in hemodialy-
sis patients [181. The present study demonstrates that
deferoxamine given intravenously also enhances aluminum
removal by peritoneal dialysis. Moreover, the current data
indicate that deferioxamine administered by the intraperitoneal
route is equally effective in enhancing the removal of aluminum,
whether comparing the increment of aluminum removal be-
tween two groups of patients or in paired studies in the same
patient.
Only 5 to 20% of plasma aluminum is ultrafilterable [18, 191,
limiting the amount of aluminum that can be removed by either
hemodialysis or peritoneal dialysis. After the administration of
deferoxamine, total plasma aluminum levels and the dialysate
to plasma aluminum concentration ratios increased. The latter
observation indicates an increase in the ultrafilterable fraction
of plasma aluminum. The rise in plasma aluminum levels and
the increase in the ultrafilterable fraction of plasma aluminum
by deferoxamine result in greatly enhanced removal of alumi-
num by peritoneal dialysis. Similar observations have been
made following the administration of deferoxamine during
hemodialysis [18].
No comparison was made of the rates of aluminum removal
by peritoneal dialysis and hemodialysis. However, the removal
of 2.64 0.56 mg of aluminum by peritoneal dialysis over two
days after deferOxamine (the sum of 1.52 .34 during the first
24 hours and 1.12 .23 during the next 24 hours) compares
favorably with the 2.93 0.49 mg removed during four hours of
hemodialysis, reported in a separate study from our dialysis
unit [18]. Since the removal of aluminum via peritoneal dialysis
may be enhanced for several days after a single infusion of
deferoxamine, little advantage is created by administering the
drug more frequently than once a week. Moreover, the addition
of the medication to the sterile dialysate less frequently will also
reduce the risk of bacterial contamination and possible perito-
nitis.
The present data do not address the efficacy or safety of
long—term treatment with intraperitoneal deferoxamine, but
only show that significant quantities of aluminum can be
removed via this route; there may be concern whether
deferioxamine can alter the characteristics of the peritoneal
membrane. The lack of evidence of local toxicity when defer-
oxamine is given over long periods by clysis [5, 7, 20] is
evidence that deferoxamine does not cause significant irritation
or inflammation.
Preliminary observations of the long—term use of intraperi-
toneal deferoxamine have been obtained in five patients under-
going treatment with CAPD or CCPD and in whom
aluminum—related bone disease has been diagnosed. They have
received intraperitoneal deferoxamine, 2 to 3 glweek, added to
the overnight exchange once a week for two to 12 months. The
patients have tolerated the treatment without any adverse
effects. Further studies are needed in a larger number of
patients to fully assess the safety and efficacy of long—term
therapy with intraperitoneal deferoxamine.
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